Bacteriophage Esc-CHP-2 for Targeted E. coli Lysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preventing and treating enteropathogenic E. coli infections, particularly in livestock, are inadequate due to the rise of antibiotic-resistant bacteria and the need for a more specific and nature-friendly alternative.

Innovation Solution

A Myoviridae bacteriophage Esc-CHP-2 isolated from nature, with a specific genome sequence, is used as an active ingredient in a composition to target and kill enteropathogenic E. coli, preventing and treating infections without harming other bacteria.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to prevent or treat enteropathogenic E. coli infections, then the treatment effectiveness is improved, but antibiotic-resistant bacteria emerge leading to treatment failure

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidantibiotic resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses bacteriophage as an intermediary agent to kill enteropathogenic E. coli bacteria. The bacteriophage specifically infects and lyses the target bacteria through a biological mechanism that does not involve antibiotics, thereby avoiding the development of antibiotic resistance while maintaining treatment effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the chemical mechanism of antibiotics with the biological mechanism of bacteriophage infection. Instead of using chemical substances that bacteria can develop resistance against, the invention uses a living virus that replicates inside and destroys the bacteria, fundamentally changing the mode of action to eliminate resistance development

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Adaptability or versatility

If broad-spectrum antibiotics are used to treat bacterial infections, then the treatment coverage is improved, but harmful effects on beneficial bacteria and environmental impact increase

Engineering Contradiction:

Improvetreatment coverageVSAvoidside effects on beneficial bacteria

Core Design Contradiction:

Adaptability or versatilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies the principle of local quality by using bacteriophage that exhibits highly specific host range. The bacteriophage is designed to infect only specific strains of enteropathogenic E. coli based on the presence of particular surface receptors, leaving other bacteria including beneficial flora completely unaffected. This localized specificity resolves the contradiction between treatment coverage and harm to beneficial bacteria

Inventive Principle:

Principle #3Local quality

3Reliability

If conventional disinfectants are used to control E. coli infections, then the disinfection effectiveness is improved, but the environmental friendliness and safety for animals decrease

Engineering Contradiction:

Improvedisinfection effectivenessVSAvoidenvironmental toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs bacteriophage as a disposable biological agent that naturally degrades after use. The bacteriophage performs its disinfection function by infecting and lysing target bacteria, then naturally dies off and decomposes in the environment without persisting as a toxic substance, unlike conventional chemical disinfectants that accumulate and cause environmental pollution

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent converts the potentially harmful property of biological agents into a beneficial outcome. The bacteriophage's natural lytic cycle, which destroys bacterial cells, is harnessed as a beneficial disinfection mechanism. The bacteria's own cell wall components and intracellular contents become harmless after lysis, and the bacteriophage itself degrades naturally, transforming what could be seen as a violent destruction process into an environmentally friendly solution

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The bacteriophage composition effectively inhibits the growth and kills enteropathogenic E. coli, reducing diarrhea and related symptoms in animals, while being specific to the target bacteria, thus minimizing side effects and environmental impact.

Implementation Method 1

Once bacteriophage infects bacteria, the bacteriophage is proliferated in the inside of the bacterial cell. After full proliferation, the progenies destroy the bacterial cell wall to escape from the host, suggesting that the bacteriophage has bacteria killing ability.

Methodology Applied

Scientific EffectBacteriophage infection:

Data Source

PatentUS10265354B2Enteropathogenic <i>E. coli </i>bacteriophage Esc-CHP-2 and use thereof for inhibiting proliferation of enteropathogenic <i>E. coli</i>

Publication Date: 2019.04.23 INTRON BIOTECHNOLOGY INC

AI summary

The present invention relates to a Myoviridae bacteriophage Esc-CHP-2 that is isolated from the nature and can kill specifically enteropathogenic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12661BP), and a method for preventing and treating the infections of enteropathogenic E. coli using the composition comprising said bacteriophage as an active ingredient.